Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East

EDMONTON, Alberta & CALGARY, Alberta–Nanostics. Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, and OncoHelix a leader in precision diagnostics, today announced their partnership to provide ClarityDX Prostate® to healthcare providers and men in the Middle East.

OncoHelix provides advanced molecular diagnostics and immune profile testing to the Middle East and North Africa (MENA) region through OncoHelix-coLAB, a state-of-the-art laboratory within Burjeel Medical City, Abu Dhabi. This facility is a joint venture between OncoHelix and Burjeel Holdings, one of the largest healthcare providers in the Middle East. The OncoHelix-coLAB facility will now also provide Nanostics’ ClarityDX Prostate diagnostic tool to men at risk of having aggressive prostate cancer. The addition of this test will further enhance patient diagnostics and treatment outcomes in the region.

“Partnering with OncoHelix, another Alberta-based company, to bring ClarityDX Prostate to men in the Middle East really shows how relevant Alberta-developed technology has become to the world,” said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. “ClarityDX Prostate is a powerful diagnostic tool that can help identify men with aggressive prostate cancer early. We want all men to benefit from early detection leading to better outcomes.”